Skip to main content

Advertisement

Advertisement

Advertisement

Advertisement

ADVERTISEMENT

Podcasts

Andreas Hochhaus, MD, on Asciminib vs Bosutinib for Pretreated CML-CP

In this podcast, Andreas Hochhaus, MD, University Medical Center Jena, Germany, discusses the use of asciminib versus bosutinib for the treatment of patients with chronic myeloid leukemia in chronic phase (CML-CP) previously given ≥2 tyrosine kinase inhibitors (TKIs). These data were presented at the virtual 2020 ASH Annual Meeting and Exposition.  
 

Advertisement

Advertisement

Advertisement

Advertisement